THC Farmaceuticals Receivables

THC Farmaceuticals posts a receivables of $640K as of June 2022. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Receivables is one piece of THC Farmaceuticals's financial statement story. At $640K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CBDG's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; THC Farmaceuticals's other metric pages and overview cover the third.

Judging THC Farmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $640K here, then scan peer and history charts to see if the gap is persistent.